Clinical evaluation of oral administration of a cholecystokinin-a receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: A multicenter dose-response study in japan

Nursing

Volumn 25, Issue 1, 1995, Pages

  Shiratori, Keiko ^a   Takeuchi, Tadashi ^a   Satake, Katsusuke ^b   Matsuno, Seiki ^c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CCK receptor antagonist; Chronic pancreatitis; Loxiglumide

Indexed keywords

AMYLASE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ RECEPTOR; DRUG DERIVATIVE; HORMONE ANTAGONIST; LOXIGLUMIDE; PROGLUMIDE; TRIACYLGLYCEROL LIPASE; TRYPSIN;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; AMYLASES; CHRONIC DISEASE; FEMALE; HORMONE ANTAGONISTS; HUMANS; LIPASE; MALE; MIDDLE AGED; PAIN; PANCREATITIS; PROGLUMIDE; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; TREATMENT OUTCOME; TRYPSIN;

EID: 18744389156     PISSN: 03604039     EISSN: 15388689     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Niederau C, Ferrell LD, Grendell JH. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology 1985; 88:1192-204.
2. Watanabe O, Baccino FM, Steer ML, et al. Supramaximal caerulein stimulation and ultrastructure of rat pancreas acinar cells: early morphological changes during development of experimental pancreatitis. Am J Physiol 1984; 246:G457-67.
3. Saluja A, Saito I, Saluja M, et al. In vivo rat acinar cell function during submaximal stimulation with caerulein. Am J Physiol 1985; 249:G702-10.
4. Elsasser HP, Adler G, Kern HF. Time course and cellular source of pancreatic regeneration following acute pancreatitis in the rat. Pancreas 1986; 1:421-9.
5. Niederau C, Liddle RA, Ferrell LD, et al. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice: evidence for cholecystokinin as major factor in the development of acute pancreatitis. J Clin Invest 1986; 78:1056-63.
6. Makovec F, Bani M, Cereda R, et al. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides 1986; 7:1159-64.
7. Wisner, JR., Renner IG. Asperlicin, a nonpeptideal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats. Pancreas 1988; 3:174-9.
8. Garcia-Montero AC, Manso MA, Rodriguez AI, et al. Therapeutic and protective effect of subcutaneous injections of L-364,718 on caerulein-induced acute pancreatitis. Pancreas 1994; 9:309-15.
9. Satake K, Kimura K, Saito T. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Digestion 1999; 60(suppl 1):64-8.
10. Ochi K, Harada H, Satake K, et al. Clinical evaluation of cholecystokinin-A-receptor antagonist (loxiglumide) for the treatment of acute pancreatitis: a preliminary clinical trial. Digestion 1999; 60(suppl 1):81-5.
11. Satake K, Matsuno S, Shiratori K, et al. Clinical evaluation of CCK-A receptor antagonist (loxiglumide) on acute symptoms during acute pancreatitis: multicenter double blind studies with nafamostat mesylate. Pancreas 1999; 19:436.
12. Warshaw AL, Banks PA, Fernandez-del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology 1998; 115:765-76.
13. Ammann RW, Muelhaupt B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology 1999; 116:1132-40.
14. Schafmeyer A, Becker HP, Werner M, et al. Plasma cholecystokinin levels in patients with chronic pancreatitis. Digestion 1985; 32:136-9.
15. Gomez-Cerezo J, Codoceo R, Fernandez-Calle P, et al. Basal and postprandial cholecystokinin values in chronic pancreatitis with and without abdominal pain. Digestion 1991; 48:134-40.
16. Garces MC, Gomez-Cerezo J, Alba D, et al. Relationship of basal and postprandial intraduodenal bile acid concentrations and plasma cholecystokinin levels with abdominal pain in patients with chronic pancreatitis. Pancreas 1998; 17:397-401.
17. Owyang C, Louie DS, Tatum D. Feedback regulation of pancreatic enzyme secretion: suppression of cholecystokinin release by trypsin. J Clin Invest 1986; 77:2042-7.
18. Layer P, Janson JBMJ, Cherian L, et al. Feedback regulation of human pancreatic secretion: effective protease inhibition of duodenal, liver, and small intestinal transit of pancreatic enzymes. Gastroenterology 1990; 98:1311-9.
19. Jin HO, Song CW, Chang TM, et al. Roles of gut hormones in negative-feedback regulation of pancreatic exocrine secretion in humans. Gastroenterology 1994; 107:1828-34.
20. Funakoshi A, Nakano I, Shinozaki H, et al. Low plasma cholecystokinin response after ingestion of a test meal in patients with chronic pancreatitis. Am J Gastroenterol 1985; 80:937-40.
21. Bozkurt T, Adler G, Koop I, et al. Plasma CCK levels in patients with pancreatic insufficiency. Dig Dis Sci 1988; 33:276-81.
22. Adler G, Reinshagen M, Beglinger C, et al. Effect of a cholecystokinin antagonist, loxiglumide, on pancreatic secretion in patients with chronic pancreatitis. Biomed Res 1990; 11:151-6.
23. Nustede R, Kohler H, Folsch UR, et al. Plasma concentrations of neurotensin and CCK in patients with chronic pancreatitis with and without enzyme substitution. Pancreas 1991; 6:260-5.
24. Layer P, Von der Ohe MR, Holst JJ, et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Gastroenterology 1997; 112:1624-34.
25. Eddes EH, Masclee AAM, Gielkens HAJ, et al. Cholecystokinin secretion in patients with chronic pancreatitis and after different types of pancreatic surgery. Pancreas 1999; 19:119-25.
26. Committee of Diagnostic Criteria for Chronic Pancreatitis. Diagnostic criteria for chronic pancreatitis. Jpn J Gastroenterol 1983;80:1863-6.
27. Lin Y, Tamakoshi A, Matsuno S, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol 2000; 35:136-41.
28. McCleane GJ. The cholecystokinin antagonist proglumide has an analgesic effect in chronic pancreatitis. Pancreas 2000; 21:324-5.
29. Rezvani A, Stokes B, Rhoads HL, et al. Proglumide exhibits delta opioid agonist properties. Alcohol Drug Res 1987; 7:135-46.
30. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesth Analg 1998; 87:1117-20.
31. Wank S, Posegna JR, De Weerth A. Cholecystokinin receptor family: molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann NY Acad Sci 1994; 713:49-66.
32. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269:G628-46.
33. Tang C, Biemond I, Lamers CBHW. Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology 1996; 111:1621-6.
34. Funakoshi A, Fukamizu Y, Miyasaka K. Mechanism of cholecystokinin-A-receptor antagonist on human pancreatic exocrine secretion. Digestion 1999; 60(suppl 1):75-80.
35. Nishimori I, Kamakura M, Fujikawa-Adachi K, et al. Cholecystokinin A and B receptor mRNA expression in human pancreas. Pancreas 1999; 19:109-13.
36. Hildebrand P, Beglinger G, Gyr K, et al. Effects of a cholecystokinin antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 1990; 85:640-6.
37. Shiratori K, Watanabe S, Chey WY, et al. Endogenous cholecystokinin drives gallbladder emptying in dogs. Am J Physiol 1986; 251:G553-8.